These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6579706)

  • 21. Platelet survival and function in animals with prosthetic mitral valve: the effect of nafazatrom.
    Al-Mondhiry H; Pierce WS; Richenbacher W
    Thromb Haemost; 1984 Oct; 52(2):99-101. PubMed ID: 6523440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction of myocardial infarction and dysrhythmic activity by nafazatrom in the conscious rat.
    Fiedler VB
    Eur J Pharmacol; 1983 Mar; 88(2-3):263-7. PubMed ID: 6852112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanism of action of nafazatrom.
    Seuter F; Busse WD
    Thromb Res Suppl; 1983; 4():75-80. PubMed ID: 6415860
    [No Abstract]   [Full Text] [Related]  

  • 24. First use of nafazatrom, a new antithrombotic drug, in pregnancy.
    Elder MG; Myatt L
    Lancet; 1984 Jun; 1(8390):1350. PubMed ID: 6145042
    [No Abstract]   [Full Text] [Related]  

  • 25. Manipulation of the local thromboxane and prostacyclin balance in vivo by the antithrombotic compounds dazoxiben, acetylsalicylic acid and nafazatrom.
    Deckmyn H; Van Houtte E; Verstraete M; Vermylen J
    Biochem Pharmacol; 1983 Sep; 32(18):2757-62. PubMed ID: 6578796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-performance liquid chromatographic determination of nafazatrom in human plasma using fluorescence detection.
    Evans LJ; Young JD; Hutchison JS; Baker LH
    J Chromatogr; 1984 Jan; 305(1):163-70. PubMed ID: 6707139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of nafazatrom on platelet function and release: relationship to symptomatic episodes in patients with peripheral vascular disease.
    Buchanan MR; Butt RW; Turpie AG
    Am Heart J; 1987 May; 113(5):1133-7. PubMed ID: 2953219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial effects of nafazatrom on ischemic reperfused myocardium.
    Shea MJ; Murtagh JJ; Jolly SR; Abrams GD; Pitt B; Lucchesi BR
    Eur J Pharmacol; 1984 Jun; 102(1):63-70. PubMed ID: 6479219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I and pharmacologic evaluation of nafazatrom in patients with cancer.
    Haas CD; Baker LH; Evans LJ
    Invest New Drugs; 1984; 2(1):13-7. PubMed ID: 6469495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interference with tumor cell-induced degradation of endothelial matrix on the antimetastatic action of nafazatrom.
    Maniglia CA; Loulakis PP; Sartorelli AC
    J Natl Cancer Inst; 1986 Apr; 76(4):739-44. PubMed ID: 3457206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nafazatrom (Bay g 6575) blunts canine hypoxic pulmonary vasoconstriction: evidence for a prostaglandin-mediated mechanism.
    Ensley RD; Rubin LJ
    Prostaglandins Leukot Med; 1985 Apr; 18(1):95-104. PubMed ID: 3923499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nafazatrom-induced salvage of ischemic myocardium in anesthetized dogs is mediated through inhibition of neutrophil function.
    Bednar M; Smith B; Pinto A; Mullane KM
    Circ Res; 1985 Jul; 57(1):131-41. PubMed ID: 2988818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The beneficial effects of nafazatrom (BAYg6575) on experimental coronary thrombosis.
    Shea MJ; Driscoll EM; Romson JL; Pitt B; Lucchesi BR
    Am Heart J; 1984 Apr; 107(4):629-37. PubMed ID: 6702555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of oral nafazatrom (= BAY g 6575) on canine coronary artery thrombosis and myocardial ischemia.
    Fiedler VB
    Basic Res Cardiol; 1983; 78(3):266-80. PubMed ID: 6615399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet aggregation in arterioles of the hamster cheek pouch and in heart transplants: its tissue-dependent influencibility by acetylsalicylic acid and nafazatrom.
    Herrmann KS; Seuter F
    Haemostasis; 1984; 14(3):281-7. PubMed ID: 6381254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nafazatrom (Bay g 6575) inhibition of tumor cell lipoxygenase activity and cellular proliferation.
    Honn KV; Dunn JR
    FEBS Lett; 1982 Mar; 139(1):65-8. PubMed ID: 6804263
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical study of a new antimetastatic compound, Nafazatrom (Bay g 6575). Effects on platelet consumption and monocyte prostaglandin production in patients with advanced cancer.
    Warrell RP; Bockman RS; Staszewski H; Maiese K
    Cancer; 1986 Apr; 57(8):1455-60. PubMed ID: 2936443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nafazatrom inhibits peroxidation of phosphatidylcholine liposomes, heart homogenate and low density lipoproteins.
    Ondrias K; Stasko A; Gergèl D; Ondriasovà E; Hromadová M
    Gen Physiol Biophys; 1997 Jun; 16(2):151-62. PubMed ID: 9437256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nafazatrom in treatment of thrombotic thrombocytopenic purpura.
    Durrant ST; Joosten P; Gordon-Smith EC
    Lancet; 1985 Oct; 2(8459):842. PubMed ID: 2864567
    [No Abstract]   [Full Text] [Related]  

  • 40. A clinical study of nafazatrom in advanced human breast cancer.
    Jones AL; Powles TJ; Forgeson GV; Coombes RC
    Cancer Chemother Pharmacol; 1991; 27(4):326-8. PubMed ID: 1998990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.